Early oxytocin treatment in infants with Prader–Willi syndrome is safe and is associated with better endocrine, metabolic and behavioral outcomes

Early oxytocin treatment in infants with Prader–Willi syndrome is safe and is associated with better endocrine, metabolic and behavioral outcomes

Abstract Background Oxytocin (OT) plays an important role in modulating behavior, social interactions and feeding. Prader–Willi syndrome (PWS), a rare genetic neurodevelopmental disorder, is a model of hypothalamic disorder including OT dysfunction. We previously showed that infants with PWS who had...

Full description

Bibliographic Details
Main Authors: Marion Valette, Gwenaelle Diene, Mélanie Glattard, Julie Cortadellas, Catherine Molinas, Sandy Faye, Grégoire Benvegnu, Kader Boulanouar, Pierre Payoux, Jean-Pierre Salles, Catherine Arnaud, Sophie Çabal, Maithé Tauber
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Prader–Willi syndrome
Oxytocin
Infants
Long-term effects
Behavior
Metabolism
Online Access:https://doi.org/10.1186/s13023-025-03560-3

Internet

https://doi.org/10.1186/s13023-025-03560-3

Similar Items